TSUMURA & CO. Logo

TSUMURA & CO.

Develops and manufactures pharmaceuticals specializing in Japanese Kampo medicine.

4540 | T

Overview

Corporate Details

ISIN(s):
JP3535800001
LEI:
Country:
Japan
Address:
港区赤坂二丁目17番11号

Description

TSUMURA & CO. is a developer and manufacturer of pharmaceuticals derived from natural substances, specializing in Kampo medicine, a traditional form of Japanese herbal medicine. The company's portfolio includes a wide range of prescription Kampo formulations, which are delivered to patients through medical institutions, as well as over-the-counter (OTC) Kampo medicines and other wellness products such as herbal bath salts. Tsumura manages a comprehensive value chain, controlling the entire process from the procurement of raw herbal materials to the production of finished granular formulations and extracts. The company's approach integrates traditional knowledge with modern scientific research and quality control standards to provide treatments across various therapeutic areas, aiming to achieve harmony between mind and body.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-11-08 07:11
確認書
Japanese ZIP 8.9 KB
2024-11-08 07:08
半期報告書-第89期(2024/04/01-2025/03/31)
Japanese ZIP 242.2 KB
2024-07-01 08:38
臨時報告書
Japanese ZIP 24.0 KB
2024-06-27 08:16
確認書
Japanese ZIP 8.9 KB
2024-06-27 08:13
有価証券報告書-第88期(2023/04/01-2024/03/31)
Japanese ZIP 2.4 MB
2024-06-27 08:03
内部統制報告書-第88期(2023/04/01-2024/03/31)
Japanese ZIP 23.9 KB
2024-02-07 06:58
確認書
Japanese ZIP 8.1 KB
2024-02-07 06:56
四半期報告書-第88期第3四半期(2023/10/01-2023/12/31)
Japanese ZIP 199.7 KB
2023-12-04 08:42
大量保有報告書
Japanese ZIP 37.5 KB
2023-11-08 06:43
確認書
Japanese ZIP 8.1 KB
2023-11-08 06:41
四半期報告書-第88期第2四半期(2023/07/01-2023/09/30)
Japanese ZIP 210.8 KB
2023-08-04 08:18
確認書
Japanese ZIP 8.1 KB
2023-08-04 08:16
四半期報告書-第88期第1四半期(2023/04/01-2023/06/30)
Japanese ZIP 188.2 KB
2023-06-29 08:05
内部統制報告書-第87期(2022/04/01-2023/03/31)
Japanese ZIP 22.3 KB
2023-06-29 08:04
確認書
Japanese ZIP 8.1 KB

Automate Your Workflow. Get a real-time feed of all TSUMURA & CO. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TSUMURA & CO.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TSUMURA & CO. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.